Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam

Three disease-modifying drugs (Nusinersen, Risdiplam and Onasemnogene abeparvovec) have been approved for SMA type I. Onasemnogene abeparvovec (GRT) can be administered in naïve patients or patients who are already being treated with Nusinersen or Risdiplam. Safety data on GRT in naïve patients or p...

Descripción completa

Detalles Bibliográficos
Autores principales: Tosi, Michele, Catteruccia, Michela, Cherchi, Claudio, Mizzoni, Irene, D’Amico, Adele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pacini Editore Srl 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628802/
https://www.ncbi.nlm.nih.gov/pubmed/36349185
http://dx.doi.org/10.36185/2532-1900-077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628802/
https://www.ncbi.nlm.nih.gov/pubmed/36349185
http://dx.doi.org/10.36185/2532-1900-077

Ejemplares similares